Search

Your search keyword '"Huang, Xiao‐Yong"' showing total 257 results
Start Over Author "Huang, Xiao‐Yong"
257 results on '"Huang, Xiao‐Yong"'

1. Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors

Author

Zhang, Dao-Han, Liang, Chen, Hu, Shu-Yang, Huang, Xiao-Yong, Yu, Lei, Meng, Xian-Long, Guo, Xiao-Jun, Zeng, Hai-Ying, Chen, Zhen, Zhang, Lv, Pei, Yan-Zi, Ye, Mu, Cai, Jia-Bin, Huang, Pei-Xin, Shi, Ying-Hong, Ke, Ai-Wu, Chen, Yi, Ji, Yuan, Shi, Yujiang Geno, Zhou, Jian, Fan, Jia, Yang, Guo-Huan, Sun, Qi-Man, Shi, Guo-Ming, and Lu, Jia-Cheng

Published
2024
Full Text
View/download PDF

3. Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

Author

Lu, Jia-Cheng, Wu, Lei-Lei, Sun, Yi-Ning, Huang, Xiao-Yong, Gao, Chao, Guo, Xiao-Jun, Zeng, Hai-Ying, Qu, Xu-Dong, Chen, Yi, Wu, Dong, Pei, Yan-Zi, Meng, Xian-Long, Zheng, Yi-Min, Liang, Chen, Zhang, Peng-Fei, Cai, Jia-Bin, Ding, Zhen-Bin, Yang, Guo-Huan, Ren, Ning, Huang, Cheng, Wang, Xiao-Ying, Gao, Qiang, Sun, Qi-Man, Shi, Ying-Hong, Qiu, Shuang-Jian, Ke, Ai-Wu, Shi, Guo-Ming, Zhou, Jian, Sun, Yi-Di, and Fan, Jia

Published
2024
Full Text
View/download PDF

4. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Author

Shi, Guo-Ming, Huang, Xiao-Yong, Wu, Dong, Sun, Hui-Chuan, Liang, Fei, Ji, Yuan, Chen, Yi, Yang, Guo-Huan, Lu, Jia-Cheng, Meng, Xian-Long, Wang, Xin-Ying, Sun, Lei, Ge, Ning-Ling, Huang, Xiao-Wu, Qiu, Shuang-Jian, Yang, Xin-Rong, Gao, Qiang, He, Yi-Feng, Xu, Yang, Sun, Jian, Ren, Zheng-Gang, Fan, Jia, and Zhou, Jian

Published
2023
Full Text
View/download PDF

18. Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

Author

Lu, Jia-Cheng, Wu, Lei-Lei, Sun, Yi-Ning, Huang, Xiao-Yong, Gao, Chao, Guo, Xiao-Jun, Zeng, Hai-Ying, Qu, Xu-Dong, Chen, Yi, Wu, Dong, Pei, Yan-Zi, Meng, Xian-Long, Zheng, Yi-Min, Liang, Chen, Zhang, Peng-Fei, Cai, Jia-Bin, Ding, Zhen-Bin, Yang, Guo-Huan, Ren, Ning, and Huang, Cheng

Subjects
CHOLANGIOCARCINOMA, T cells, IMMUNITY, CD8 antigen, TUMOR microenvironment, OXALIPLATIN
Abstract

Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma. Here, we examine the single-cell transcriptional and TCR profiles of 18 tumor tissues pre- and post- therapy of gemcitabine plus oxaliplatin, in combination with lenvatinib and anti-PD1 antibody for intrahepatic cholangiocarcinoma. We find that high CD8 GZMB+ and CD8 proliferating proportions and a low Macro CD5L+ proportion predict good response to the therapy. In patients with a poor response, the CD8 GZMB+ and CD8 proliferating proportions are increased, but the CD8 GZMK+ proportion is decreased after the therapy. Transition of CD8 proliferating and CD8 GZMB+ to CD8 GZMK+ facilitates good response to the therapy, while Macro CD5L+–CD8 GZMB+ crosstalk impairs the response by increasing CTLA4 in CD8 GZMB+. Anti-CTLA4 antibody reverses resistance of the therapy in intrahepatic cholangiocarcinoma. Our data provide a resource for predicting response of the combination therapy and highlight the importance of CD8+T-cell status conversion and exhaustion induced by Macro CD5L+ in influencing the response, suggesting future avenues for cancer treatment optimization. The role of the tumor microenvironment in immunotherapy response in intrahepatic cholangiocarcinoma remains unclear. Here, single cell RNA and TCR sequencing of samples before and after immunotherapy highlights the role of CD8 T-cell status conversion and exhaustion induced by Macro CD5L+ in treatment response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Corrigendum to: “PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma” [J Hepatol 77 (2022) 163-176]

Author

Wei, Chuan-Yuan, primary, Zhu, Meng-Xuan, additional, Zhang, Peng-Fei, additional, Huang, Xiao-Yong, additional, Wan, Jin-Kai, additional, Yao, Xiu-Zhong, additional, Hu, Ze-Tao, additional, Chai, Xiao-Qiang, additional, Peng, Rui, additional, Yang, Xuan, additional, Gao, Chao, additional, Gao, Jian, additional, Wang, Si-Wei, additional, Zheng, Yi-Min, additional, Tang, Zheng, additional, Gao, Qiang, additional, Zhou, Jian, additional, Cai, Jia-Bin, additional, Ke, Ai-Wu, additional, and Fan, Jia, additional

Published
2023
Full Text
View/download PDF

22. Application of a Single-Cell-RNA-Based Biological-Plausible Graph Neural Network in Diagnosis of Primary Liver Tumours

Author

Zhang, Dao-Han, primary, Liang, Chen, additional, Huang, Xiao-Yong, additional, Yu, Lei, additional, Meng, Xianlong, additional, Guo, Xiao-Jun, additional, Zeng, Hai-Ying, additional, Chen, Zhen, additional, Zhang, Lv, additional, Pei, Yanzi, additional, Hu, Shu-Yang, additional, Ye, Mu, additional, Cai, Jiabin, additional, Huang, Pei-Xin, additional, Shi, Ying-Hong, additional, Ke, Aiwu, additional, Chen, Yi, additional, Ji, Yuan, additional, Shi, Yujiang Geno, additional, Zhou, Jian, additional, Fan, Jia, additional, Yang, Guo-Huang, additional, Sun, Qi-Man, additional, Shi, Guo-Ming, additional, and Lu, Jia-Cheng, additional

Published
2023
Full Text
View/download PDF

23. The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion

Author

Meng, Xian-Long, primary, Lu, Jia-Cheng, additional, Zeng, Hai-Ying, additional, Chen, Zhen, additional, Guo, Xiao-Jun, additional, Gao, Chao, additional, Pei, Yan-Zi, additional, Hu, Shu-Yang, additional, Ye, Mu, additional, Sun, Qi-Man, additional, Yang, Guo-Huang, additional, Cai, Jia-Bin, additional, Huang, Pei-Xin, additional, Yv, Lei, additional, Zhang, Lv, additional, Shi, Ying-Hong, additional, Ke, Ai-Wu, additional, Zhou, Jian, additional, Fan, Jia, additional, Chen, Yi, additional, Huang, Xiao-Yong, additional, and Shi, Guo-Ming, additional

Published
2022
Full Text
View/download PDF

24. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Author

Shi, Guo‐Ming, primary, Huang, Xiao‐Yong, additional, Wen, Tian‐Fu, additional, Song, Tian‐Qiang, additional, Kuang, Ming, additional, Mou, Hai‐Bo, additional, Bao, Le‐Qun, additional, Zhao, Hai‐Tao, additional, Zhao, Hong, additional, Feng, Xie‐Lin, additional, Zhang, Bi‐Xiang, additional, Peng, Tao, additional, Zhang, Yu‐Bao, additional, Li, Xiang‐Cheng, additional, Yu, Hong‐Sheng, additional, Cao, Yu, additional, Liu, Lian‐Xin, additional, Zhang, Ti, additional, Wang, Wei‐Lin, additional, Ran, Jiang‐Hua, additional, Liu, Ying‐Bin, additional, Gong, Wei, additional, Chen, Ming‐Xia, additional, Cao, Lian, additional, Luo, Yang, additional, Wang, Yan, additional, Zhou, Hui, additional, Yang, Guo‐Huan, additional, Fan, Jia, additional, and Zhou, Jian, additional

Published
2022
Full Text
View/download PDF

27. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma

Author

Wei, Chuan-Yuan, primary, Zhu, Meng-Xuan, additional, Zhang, Peng-Fei, additional, Huang, Xiao-Yong, additional, Wan, Jin-Kai, additional, Yao, Xiu-Zhong, additional, Hu, Ze-Tao, additional, Chai, Xiao-Qiang, additional, Peng, Rui, additional, Yang, Xuan, additional, Gao, Chao, additional, Gao, Jian, additional, Wang, Si-Wei, additional, Zheng, Yi-Min, additional, Tang, Zheng, additional, Gao, Qiang, additional, Zhou, Jian, additional, Fan, Jia-Bin, additional, Ke, Ai-Wu, additional, and Fan, Jia, additional

Published
2022
Full Text
View/download PDF

32. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.

Author

Shi, Guo‐Ming, Huang, Xiao‐Yong, Wen, Tian‐Fu, Song, Tian‐Qiang, Kuang, Ming, Mou, Hai‐Bo, Bao, Le‐Qun, Zhao, Hai‐Tao, Zhao, Hong, Feng, Xie‐Lin, Zhang, Bi‐Xiang, Peng, Tao, Zhang, Yu‐Bao, Li, Xiang‐Cheng, Yu, Hong‐Sheng, Cao, Yu, Liu, Lian‐Xin, Zhang, Ti, Wang, Wei‐Lin, and Ran, Jiang‐Hua

Subjects
*CHINESE people, *FIBROBLAST growth factor 2, *FIBROBLAST growth factor receptors, *CHOLANGIOCARCINOMA
Abstract

Objective: This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background: Pemigatinib provided clinical benefits for previously treated patients with cholangiocarcinoma carrying FGFR2 fusions or rearrangements and was approved for this indication in multiple countries. Methods: In this ongoing, multicenter, single‐arm, phase II study, adult patients with locally advanced or metastatic cholangiocarcinoma carrying centrally confirmed FGFR2 fusions or rearrangements who had progressed on ≥1 systemic therapy received 13.5 mg oral pemigatinib once daily (3‐week cycle; 2 weeks on, 1 week off) until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was objective response rate (ORR) assessed by an independent radiology review committee. Results: As of January 29, 2021, 31 patients were enrolled. The median follow‐up was 5.1 months (range, 1.5–9.3). Among 30 patients with FGFR2 fusions or rearrangements evaluated for efficacy, 15 patients achieved partial response (ORR, 50.0%; 95% confidence interval [CI], 31.3–68.7); 15 achieved stable disease, contributing to a disease control rate of 100% (95% CI, 88.4–100). The median time to response was 1.4 months (95% CI, 1.3–1.4), the median duration of response was not reached, and the median progression‐free survival was 6.3 months (95% CI, 4.9–not estimable [NE]). Eight (25.8%) of 31 patients had ≥grade 3 treatment‐emergent adverse events. Hyperphosphatemia, hypophosphatasemia, nail toxicities, and ocular disorders were mostly

Published
2023
Full Text
View/download PDF

33. Ubiquitin-Specific Protease 7 Accelerates p14ARF Degradation by Deubiquitinating Thyroid Hormone Receptor-Interacting Protein 12 and Promotes Hepatocellular Carcinoma Progression

Author

Cai, Jia-Bin, Shi, Guo-Ming, Dong, Zhao-Ru, Ke, Ai-Wu, Ma, Hong-Hui, Gao, Qiang, Shen, Zao-Zhuo, Huang, Xiao-Yong, Chen, Hao, Yu, Ding-Dang, Liu, Li-Xin, Zhang, Peng-Fei, Zhang, Chi, Hu, Mei-Yu, Yang, Liu-Xiao, Shi, Ying-Hong, Wang, Xiao-Ying, Ding, Zhen-Bin, Qiu, Shuang-Jian, Sun, Hui-Chuan, Zhou, Jian, Shi, Yujiang G., and Fan, Jia

Published
2015
Full Text
View/download PDF

35. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma

Author

Guo, Xiao-Jun, primary, Lu, Jia-Cheng, additional, Zeng, Hai-Ying, additional, Zhou, Rong, additional, Sun, Qi-Man, additional, Yang, Guo-Huan, additional, Pei, Yan-Zi, additional, Meng, Xian-Long, additional, Shen, Ying-Hao, additional, Zhang, Peng-Fei, additional, Cai, Jia-Bin, additional, Huang, Pei-Xin, additional, Ke, Ai-Wu, additional, Shi, Ying-Hong, additional, Zhou, Jian, additional, Fan, Jia, additional, Chen, Yi, additional, Yang, Liu-Xiao, additional, Shi, Guo-Ming, additional, and Huang, Xiao-Yong, additional

Published
2021
Full Text
View/download PDF

36. Additional file 2 of circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma

Author

Xu, Ya-Ping, Dong, Ze-Ning, Wang, Si-Wei, Zheng, Yi-Min, Zhang, Chi, Zhou, Ying-Qun, Zhao, Yu-Jie, Zhao, Yan, Wang, Feng, Peng, Rui, Tang, Mao-Chun, Bai, Dou-sheng, Huang, Xiao-Yong, and Guo, Chuan-Yong

Abstract

Additional file 2: Supplementary Table 1. The primers used in this article.

Published
2021
Full Text
View/download PDF

37. Additional file 3 of circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma

Author

Xu, Ya-Ping, Dong, Ze-Ning, Wang, Si-Wei, Zheng, Yi-Min, Zhang, Chi, Zhou, Ying-Qun, Zhao, Yu-Jie, Zhao, Yan, Wang, Feng, Peng, Rui, Tang, Mao-Chun, Bai, Dou-sheng, Huang, Xiao-Yong, and Guo, Chuan-Yong

Abstract

Additional file 3: Supplementary Table 2. The antibodies used in the article.

Published
2021
Full Text
View/download PDF

40. Additional file 1 of circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma

Author

Xu, Ya-Ping, Dong, Ze-Ning, Wang, Si-Wei, Zheng, Yi-Min, Zhang, Chi, Zhou, Ying-Qun, Zhao, Yu-Jie, Zhao, Yan, Wang, Feng, Peng, Rui, Tang, Mao-Chun, Bai, Dou-sheng, Huang, Xiao-Yong, and Guo, Chuan-Yong

Abstract

Additional file 1: Supplementary Fig. 1. The Expression of circHMGCS1–016 in ICC Tissues. A. The expression of 5 circRNAs randomly selected from the circRNA-seq was investigated in the 4 ICC samples used for small circRNA-Seq by qRT-PCR analysis; B. Significant consistency (R2 = 0.9013, p

Published
2021
Full Text
View/download PDF

43. Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.

Author

Jian, Zhou, primary, Fan, Jia, additional, Shi, Guo-Ming, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Yang, Guo-Huan, additional, Ji, Yuan, additional, Chen, Yi, additional, Liang, Fei, additional, Lu, Jia-Cheng, additional, Ge, Ning-Ling, additional, Sun, Hui-Chuan, additional, Huang, Xiao-Wu, additional, Qiu, Shuang-Jian, additional, He, Yi-Feng, additional, Yang, Xin-Rong, additional, Xu, Yang, additional, Gao, Qiang, additional, and Sun, Jian, additional

Published
2021
Full Text
View/download PDF

44. Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.

Author

Jian, Zhou, primary, Fan, Jia, additional, Shi, Guo-Ming, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Liang, Fei, additional, Yang, Guo-Huan, additional, Lu, Jia-Cheng, additional, Chen, Yi, additional, Ge, Ning-Ling, additional, Ji, Yuan, additional, Hou, YY, additional, Sun, Hui-Chuan, additional, Qiu, Shuang-Jian, additional, Ye, Qing-Hai, additional, Huang, Xiao-Wu, additional, Shi, Ying-Hong, additional, Gao, Qiang, additional, Yang, Xin-Rong, additional, and Wang, Xiao-Ying, additional

Published
2021
Full Text
View/download PDF

45. Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.

Author

Shi, Guo-Ming, primary, Jian, Zhou, additional, Fan, Jia, additional, Huang, Xiao-Yong, additional, Wu, Dong, additional, Liang, Fei, additional, Lu, Jia-Cheng, additional, Yang, Guo-Huan, additional, Chen, Yi, additional, Ge, Ning-Ling, additional, Ji, Yuan, additional, Hou, YY, additional, Sun, Hui-Chuan, additional, Qiu, Shuang-Jian, additional, Ye, Qing-Hai, additional, Huang, Xiao-Wu, additional, Shi, Ying-Hong, additional, Gao, Qiang, additional, Yang, Xin-Rong, additional, and Wang, Zheng, additional

Published
2021
Full Text
View/download PDF

46. Additional file 5 of Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

Author

Huang, Xiao-Yong, Zhang, Peng-Fei, Chuan-Yuan Wei, Peng, Rui, Lu, Jia-Cheng, Gao, Chao, Cai, Jia-Bing, Yang, Xuan, Fan, Jia, Ke, Ai-Wu, Zhou, Jian, and Shi, Guo-Ming

Abstract

Additional file 5: Figure S1. a. The agreement between RNA-seq and qRT-PCR results; b. A negative relationship between CD8 and circMET; c. The relationship between CD4+ and CD8+ T cells in HCC tissues and the overall survival and cumulative recurrence of HCC patients was analyzed in 209 HCC patients. Figure S2. a. The expression of miR-30a/b/c/d/e-5p in HepG2 and HCCLM3 cells was determined by qRT-PCR; b. The expression of snail in HCC cells interfered with miR-30a/b/c/d/e-5p, (here we only showed miR-30b/c/d -5p); c. The chip peaks over chromosomes in snail Chip-seq; d The repertoire of snail-binding sites in HCC cell lines; Figure S3. The expression of 27 genes from the TCGA. Figure S4. a. The luciferase activity of DPP4 was upregulated in cells cotransfected with the Snail DDP4-promoter and 21,975 + TK/ 21,976 + TK; b. The luciferase activity of PDGFB after cotransfection of Snail and PDGFB vectors; c. The luciferase activity of CSPP1 after cotransfection of Snail and CSPP1 vectors; d. Snail interacts with distant sites 140,810 and 96,828 of DPP4 as enhancer elements to upregulate the DPP4 expression. Figure S5. a. The DPP4 level in Hep1–6 cells interfered with si-miR-30b-5p or si-miR-30c-5p or si-miR-30d-5p; b. Chemokine chips were used to determine the differences in chemokines between the sera of mice implanted with Hep-1-6-snail and the sera of mice implanted with Hep-1-6-shmiR-30s cells; c. Images of Hep1–6 tumors from each group and Tumor growth curves of Hep-1-6 tumors from each group(n = 3); d. Images of Hep1–6-circMET and Hep1–6-snail tumors from each group and Tumor growth curves of Hep-1-6-circMET and Hep1–6-snail tumors from each group (n = 3).

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results